Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases: Lessons from a Quarter Century

Sara Mheid; Stefan Allen; Sylvia S.W. Ng; William A. Hall; Nina N. Sanford; Todd A. Aguilera; Ahmed M. Elamir; Rana Bahij; Martijn P.W. Intven; Ganesh Radhakrishna; Issa Mohamad; Jeremy De Leon; Hendrick Tan; Shirley Lewis; Cihan Gani; Teo Stanecu; Veronica Dell’Acqua; Ali Hosni

doi:10.3390/curroncol30100667

Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases: Lessons from a Quarter Century

Sara Mheid
, Stefan Allen
, Sylvia S.W. Ng
, William A. Hall
, Nina N. Sanford
, Todd A. Aguilera
, Ahmed M. Elamir
, Rana Bahij
, Martijn P.W. Intven
, Ganesh Radhakrishna
, Issa Mohamad
, Jeremy De Leon
, Hendrick Tan
, Shirley Lewis
, Cihan Gani
, Teo Stanecu
, Veronica Dell’Acqua
, Ali Hosni^*

^*Corresponding author for this work

University of Toronto
Dalhousie University
Medical College of Wisconsin
The University of Texas Southwestern Medical Center
University Medical Center Utrecht
The Christie NHS Foundation Trust
King Hussein Cancer Center
GenesisCare
PathWest Laboratory Medicine WA
Kasturba Medical College
University Hospital Tübingen
Medical Affairs and Clinical Research

Research output: Contribution to journal › Journal article › Research › peer-review

137 Downloads (Pure)

Abstract

The utilization of stereotactic body radiation therapy for the treatment of liver metastasis has been widely studied and has demonstrated favorable local control outcomes. However, several predictive factors play a crucial role in the efficacy of stereotactic body radiation therapy, such as the number and size (volume) of metastatic liver lesions, the primary tumor site (histology), molecular biomarkers (e.g., KRAS and TP53 mutation), the use of systemic therapy prior to SBRT, the radiation dose, and the use of advanced technology and organ motion management during SBRT. These prognostic factors need to be considered when clinical trials are designed to evaluate the efficacy of SBRT for liver metastases.

Original language	English
Journal	Current Oncology
Volume	30
Issue number	10
Pages (from-to)	9230-9243
ISSN	1718-7729
DOIs	https://doi.org/10.3390/curroncol30100667
Publication status	Published - Oct 2023

Keywords

liver
oligometastases
SBRT

Documents & Links

10.3390/curroncol30100667Licence: CC BY

Open Access VersionFinal published version, 331 KBLicence: CC BY

SDU Link

Check access to the material in SDU Library's search engine

Cite this

Mheid, S., Allen, S., Ng, S. S. W., Hall, W. A., Sanford, N. N., Aguilera, T. A., Elamir, A. M., Bahij, R., Intven, M. P. W., Radhakrishna, G., Mohamad, I., De Leon, J., Tan, H., Lewis, S., Gani, C., Stanecu, T., Dell’Acqua, V., & Hosni, A. (2023). Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases: Lessons from a Quarter Century. Current Oncology, 30(10), 9230-9243. https://doi.org/10.3390/curroncol30100667

@article{48f3124eb92d444d8a5a813e7d6942ff,

title = "Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases: Lessons from a Quarter Century",

abstract = "The utilization of stereotactic body radiation therapy for the treatment of liver metastasis has been widely studied and has demonstrated favorable local control outcomes. However, several predictive factors play a crucial role in the efficacy of stereotactic body radiation therapy, such as the number and size (volume) of metastatic liver lesions, the primary tumor site (histology), molecular biomarkers (e.g., KRAS and TP53 mutation), the use of systemic therapy prior to SBRT, the radiation dose, and the use of advanced technology and organ motion management during SBRT. These prognostic factors need to be considered when clinical trials are designed to evaluate the efficacy of SBRT for liver metastases.",

keywords = "liver, oligometastases, SBRT",

author = "Sara Mheid and Stefan Allen and Ng, \{Sylvia S.W.\} and Hall, \{William A.\} and Sanford, \{Nina N.\} and Aguilera, \{Todd A.\} and Elamir, \{Ahmed M.\} and Rana Bahij and Intven, \{Martijn P.W.\} and Ganesh Radhakrishna and Issa Mohamad and \{De Leon\}, Jeremy and Hendrick Tan and Shirley Lewis and Cihan Gani and Teo Stanecu and Veronica Dell{\textquoteright}Acqua and Ali Hosni",

year = "2023",

month = oct,

doi = "10.3390/curroncol30100667",

language = "English",

volume = "30",

pages = "9230--9243",

journal = "Current Oncology",

issn = "1718-7729",

publisher = "MDPI",

number = "10",

}

Mheid, S, Allen, S, Ng, SSW, Hall, WA, Sanford, NN, Aguilera, TA, Elamir, AM, Bahij, R, Intven, MPW, Radhakrishna, G, Mohamad, I, De Leon, J, Tan, H, Lewis, S, Gani, C, Stanecu, T, Dell’Acqua, V & Hosni, A 2023, 'Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases: Lessons from a Quarter Century', Current Oncology, vol. 30, no. 10, pp. 9230-9243. https://doi.org/10.3390/curroncol30100667

TY - JOUR

T1 - Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases

T2 - Lessons from a Quarter Century

AU - Mheid, Sara

AU - Allen, Stefan

AU - Ng, Sylvia S.W.

AU - Hall, William A.

AU - Sanford, Nina N.

AU - Aguilera, Todd A.

AU - Elamir, Ahmed M.

AU - Bahij, Rana

AU - Intven, Martijn P.W.

AU - Radhakrishna, Ganesh

AU - Mohamad, Issa

AU - De Leon, Jeremy

AU - Tan, Hendrick

AU - Lewis, Shirley

AU - Gani, Cihan

AU - Stanecu, Teo

AU - Dell’Acqua, Veronica

AU - Hosni, Ali

PY - 2023/10

Y1 - 2023/10

N2 - The utilization of stereotactic body radiation therapy for the treatment of liver metastasis has been widely studied and has demonstrated favorable local control outcomes. However, several predictive factors play a crucial role in the efficacy of stereotactic body radiation therapy, such as the number and size (volume) of metastatic liver lesions, the primary tumor site (histology), molecular biomarkers (e.g., KRAS and TP53 mutation), the use of systemic therapy prior to SBRT, the radiation dose, and the use of advanced technology and organ motion management during SBRT. These prognostic factors need to be considered when clinical trials are designed to evaluate the efficacy of SBRT for liver metastases.

AB - The utilization of stereotactic body radiation therapy for the treatment of liver metastasis has been widely studied and has demonstrated favorable local control outcomes. However, several predictive factors play a crucial role in the efficacy of stereotactic body radiation therapy, such as the number and size (volume) of metastatic liver lesions, the primary tumor site (histology), molecular biomarkers (e.g., KRAS and TP53 mutation), the use of systemic therapy prior to SBRT, the radiation dose, and the use of advanced technology and organ motion management during SBRT. These prognostic factors need to be considered when clinical trials are designed to evaluate the efficacy of SBRT for liver metastases.

KW - liver

KW - oligometastases

KW - SBRT

U2 - 10.3390/curroncol30100667

DO - 10.3390/curroncol30100667

M3 - Journal article

C2 - 37887567

AN - SCOPUS:85175273499

SN - 1718-7729

VL - 30

SP - 9230

EP - 9243

JO - Current Oncology

JF - Current Oncology

IS - 10

ER -

Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases: Lessons from a Quarter Century

Abstract

Keywords

Documents & Links

SDU Link

Fingerprint

Cite this